Fed. Circ. Rules Enbrel Doesn't Infringe Ariad Patent

Law360, New York (June 1, 2009, 12:00 AM EDT) -- A federal appeals court has ruled that Amgen Inc.'s arthritis drug Enbrel does not infringe an Ariad Pharmaceuticals Inc. patent, affirming an order by a district court.

In an opinion written by Judge Paul R. Michel, the U.S. Court of Appeals for the Federal Circuit ruled Monday that Magistrate Judge Mary Pat Thynge, of the U.S. District Court for the District of Delaware, was right to grant Amgen's motion for summary judgment that it did not infringe U.S. Patent Number 6,410,516.

An attorney for Amgen could...
To view the full article, register now.